Abcellera Biologics IncNASDAQ:ABCL
- LAST PRICE3.8300
- TODAY'S CHANGE (%)-0.0200 (-0.5195%)
- Bid / Lots3.8300/ 36
- Ask / Lots3.8400/ 14
- Open / Previous Close3.9200 / 3.8500
- Day Range
- 52 Week Range
- Volume742,443
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABCL |
|---|---|---|
| 09:32 ET | 6974 | 3.96 |
| 09:34 ET | 39435 | 4 |
| 09:36 ET | 5077 | 3.97 |
| 09:38 ET | 5017 | 3.955 |
| 09:39 ET | 20050 | 3.945 |
| 09:41 ET | 8694 | 3.945 |
| 09:43 ET | 11338 | 3.94 |
| 09:45 ET | 2983 | 3.9389 |
| 09:48 ET | 4299 | 3.91 |
| 09:50 ET | 3400 | 3.91 |
| 09:52 ET | 2245 | 3.925 |
| 09:54 ET | 3634 | 3.93 |
| 09:56 ET | 1592 | 3.925 |
| 09:57 ET | 30014 | 3.9199 |
| 09:59 ET | 8428 | 3.935 |
| 10:01 ET | 6350 | 3.93 |
| 10:03 ET | 5192 | 3.965 |
| 10:06 ET | 6218 | 3.96 |
| 10:08 ET | 4811 | 3.935 |
| 10:10 ET | 7147 | 3.94 |
| 10:12 ET | 2864 | 3.95 |
| 10:14 ET | 3092 | 3.95 |
| 10:15 ET | 18254 | 3.92 |
| 10:17 ET | 6368 | 3.92 |
| 10:19 ET | 8246 | 3.94 |
| 10:21 ET | 7146 | 3.94 |
| 10:24 ET | 4618 | 3.92 |
| 10:26 ET | 3687 | 3.92 |
| 10:28 ET | 12745 | 3.95 |
| 10:30 ET | 9550 | 3.945 |
| 10:32 ET | 12692 | 3.935 |
| 10:33 ET | 1800 | 3.925 |
| 10:35 ET | 2627 | 3.94 |
| 10:37 ET | 4512 | 3.93 |
| 10:39 ET | 5361 | 3.93 |
| 10:42 ET | 1300 | 3.925 |
| 10:44 ET | 5100 | 3.925 |
| 10:46 ET | 1396 | 3.925 |
| 10:48 ET | 2485 | 3.925 |
| 10:50 ET | 14632 | 3.959 |
| 10:51 ET | 16873 | 3.952 |
| 10:53 ET | 4989 | 3.9697 |
| 10:55 ET | 8631 | 3.965 |
| 10:57 ET | 25157 | 3.95 |
| 11:00 ET | 4374 | 3.955 |
| 11:02 ET | 3528 | 3.95 |
| 11:04 ET | 5573 | 3.945 |
| 11:06 ET | 6504 | 3.945 |
| 11:08 ET | 600 | 3.945 |
| 11:09 ET | 1665 | 3.945 |
| 11:11 ET | 4725 | 3.94 |
| 11:13 ET | 7060 | 3.93 |
| 11:15 ET | 2865 | 3.925 |
| 11:18 ET | 1750 | 3.925 |
| 11:20 ET | 8044 | 3.9194 |
| 11:22 ET | 1851 | 3.925 |
| 11:24 ET | 6425 | 3.9101 |
| 11:26 ET | 3378 | 3.915 |
| 11:27 ET | 1210 | 3.915 |
| 11:29 ET | 2085 | 3.915 |
| 11:31 ET | 500 | 3.915 |
| 11:33 ET | 1983 | 3.91 |
| 11:36 ET | 27462 | 3.94 |
| 11:38 ET | 1700 | 3.935 |
| 11:40 ET | 970 | 3.935 |
| 11:42 ET | 1856 | 3.935 |
| 11:44 ET | 13265 | 3.9384 |
| 11:45 ET | 2430 | 3.9413 |
| 11:47 ET | 17657 | 3.94 |
| 11:49 ET | 767 | 3.94 |
| 11:51 ET | 400 | 3.945 |
| 11:54 ET | 10491 | 3.9341 |
| 11:56 ET | 499 | 3.93 |
| 11:58 ET | 4467 | 3.925 |
| 12:00 ET | 792 | 3.92 |
| 12:03 ET | 5673 | 3.915 |
| 12:05 ET | 981 | 3.91 |
| 12:07 ET | 691 | 3.91 |
| 12:09 ET | 203 | 3.915 |
| 12:12 ET | 770 | 3.915 |
| 12:14 ET | 400 | 3.915 |
| 12:16 ET | 4387 | 3.9 |
| 12:18 ET | 5393 | 3.92 |
| 12:20 ET | 7445 | 3.9 |
| 12:21 ET | 1100 | 3.89 |
| 12:23 ET | 1782 | 3.895 |
| 12:25 ET | 14317 | 3.9091 |
| 12:27 ET | 700 | 3.905 |
| 12:30 ET | 4405 | 3.9 |
| 12:32 ET | 2591 | 3.89 |
| 12:34 ET | 5088 | 3.89 |
| 12:36 ET | 1400 | 3.9 |
| 12:38 ET | 600 | 3.905 |
| 12:39 ET | 6655 | 3.89 |
| 12:41 ET | 3200 | 3.895 |
| 12:43 ET | 518 | 3.89 |
| 12:45 ET | 2115 | 3.895 |
| 12:48 ET | 2299 | 3.885 |
| 12:50 ET | 687 | 3.88 |
| 12:52 ET | 11053 | 3.875 |
| 12:54 ET | 100 | 3.87 |
| 12:56 ET | 2318 | 3.87 |
| 12:57 ET | 1387 | 3.865 |
| 12:59 ET | 622 | 3.86 |
| 01:01 ET | 1058 | 3.86 |
| 01:03 ET | 7039 | 3.85 |
| 01:06 ET | 6793 | 3.8499 |
| 01:08 ET | 1661 | 3.8488 |
| 01:10 ET | 300 | 3.85 |
| 01:12 ET | 400 | 3.84 |
| 01:14 ET | 1784 | 3.84 |
| 01:15 ET | 1861 | 3.835 |
| 01:17 ET | 8657 | 3.84 |
| 01:19 ET | 100 | 3.84 |
| 01:21 ET | 350 | 3.8488 |
| 01:24 ET | 13804 | 3.85 |
| 01:26 ET | 8700 | 3.832 |
| 01:28 ET | 16263 | 3.83 |
| 01:32 ET | 600 | 3.83 |
May 8, 2024
DJ AbCellera Biologics Is Maintained at Overweight by Keybanc, from 2:29PM ET on Wednesday May 08, 2024 by Dow Jones
2:29PM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
AbCellera Reports Q1 2024 Business Results, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow JonesPress Release: AbCellera Reports Q1 2024 Business Results, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
May 1, 2024
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies, from 9:00AM ET on Wednesday May 01, 2024 by Dow Jones
9:00AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Abcellera Biologics Inc | 1.1B | -7.6x | --- |
Silence Therapeutics PLC | 968.2M | -14.2x | --- |
Bicycle Therapeutics PLC | 965.5M | -5.0x | --- |
Immatics NV | 1.1B | -9.0x | --- |
Cullinan Therapeutics Inc | 1.1B | -7.2x | --- |
Verona Pharma PLC | 1.1B | -17.6x | --- |
Company Information
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
Contact Information
- Headquarters
- 2215 Yukon StreetVANCOUVER, BC, Canada V5Y 0A1
- Phone
- 604-559-9005
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Carl Hansen
- Co-Founder, Chief Operating Officer, Director
- Veronique Lecault
- Chief Financial Officer
- Andrew Booth
- Chief Compliance Officer, Corporate Secretary, Chief Legal Officer
- Tryn Stimart
- Chief Commercial Officer
- Neil Aubuchon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $35.8M |
Shares Outstanding | 293.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-0.51 |
Book Value | $3.96 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | 31.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -634.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
